JP2005532331A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005532331A5 JP2005532331A5 JP2004506805A JP2004506805A JP2005532331A5 JP 2005532331 A5 JP2005532331 A5 JP 2005532331A5 JP 2004506805 A JP2004506805 A JP 2004506805A JP 2004506805 A JP2004506805 A JP 2004506805A JP 2005532331 A5 JP2005532331 A5 JP 2005532331A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- pharmaceutical composition
- lower alkyl
- fatty acid
- acid oxidation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 BC(C)(*(**)C(*)(*)C(*)(*)N1CC(**)O)C1(*)S Chemical compound BC(C)(*(**)C(*)(*)C(*)(*)N1CC(**)O)C1(*)S 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38278102P | 2002-05-21 | 2002-05-21 | |
| US45933203P | 2003-03-31 | 2003-03-31 | |
| PCT/US2003/016277 WO2003099281A2 (en) | 2002-05-21 | 2003-05-21 | Administration of a partial fatty acid inhibitor such as ranolazine for the treatment of diabetes |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005532331A JP2005532331A (ja) | 2005-10-27 |
| JP2005532331A5 true JP2005532331A5 (https=) | 2006-07-06 |
| JP4546824B2 JP4546824B2 (ja) | 2010-09-22 |
Family
ID=29586970
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004506805A Expired - Fee Related JP4546824B2 (ja) | 2002-05-21 | 2003-05-21 | 糖尿病を処置する方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US20040063717A1 (https=) |
| EP (2) | EP1505977B1 (https=) |
| JP (1) | JP4546824B2 (https=) |
| KR (1) | KR101030943B1 (https=) |
| CN (1) | CN100551370C (https=) |
| AU (1) | AU2003248558B8 (https=) |
| BR (1) | BR0311161A (https=) |
| CA (1) | CA2486712C (https=) |
| ES (1) | ES2523873T3 (https=) |
| IL (4) | IL165304A0 (https=) |
| MX (1) | MXPA04011530A (https=) |
| NO (1) | NO330336B1 (https=) |
| NZ (1) | NZ536678A (https=) |
| RU (1) | RU2320343C2 (https=) |
| WO (1) | WO2003099281A2 (https=) |
| ZA (1) | ZA200409331B (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003248558B8 (en) | 2002-05-21 | 2009-07-09 | Gilead Sciences, Inc. | Method of treating diabetes |
| US8822473B2 (en) | 2002-05-21 | 2014-09-02 | Gilead Sciences, Inc. | Method of treating diabetes |
| US20060177502A1 (en) * | 2005-01-06 | 2006-08-10 | Srikonda Sastry | Sustained release pharmaceutical formulations |
| CA2678515A1 (en) * | 2007-02-13 | 2008-08-21 | Cv Therapeutics, Inc. | Use of ranolazine for the treatment of cardiovascular diseases |
| CA2678319A1 (en) * | 2007-02-13 | 2008-08-21 | Cv Therapeutics, Inc. | Use of ranolazine for the treatment of coronary microvascular diseases |
| US20080193530A1 (en) * | 2007-02-13 | 2008-08-14 | Brent Blackburn | Use of ranolazine for the treatment of non-coronary microvascular diseases |
| US20090111826A1 (en) * | 2007-02-13 | 2009-04-30 | Louis Lange | Use of ranolazine for the treatment of cardiovascular diseases |
| WO2008116083A1 (en) * | 2007-03-22 | 2008-09-25 | Cv Therapeutics, Inc. | Use of ranolazine for elevated brain-type natriuretic peptide |
| CA2681444A1 (en) * | 2007-04-12 | 2008-10-23 | Cv Therapeutics, Inc. | Ranolazine for enhancing insulin secretion |
| CN101678017A (zh) * | 2007-05-31 | 2010-03-24 | Cv医药有限公司 | 治疗糖尿病的方法 |
| ES2402675T3 (es) * | 2007-05-31 | 2013-05-07 | Gilead Palo Alto, Inc. | Ranolazina para el péptido natriurético de tipo cerebral a niveles elevados |
| RU2442585C2 (ru) * | 2007-05-31 | 2012-02-20 | Си Ви Терапьютикс, Инк. | Способ лечения диабета |
| US20090012103A1 (en) * | 2007-07-05 | 2009-01-08 | Matthew Abelman | Substituted heterocyclic compounds |
| CA2713521A1 (en) * | 2008-02-06 | 2009-08-13 | Gilead Palo Alto, Inc. | Use of ranolazine for treating pain |
| US20110250273A1 (en) * | 2008-12-11 | 2011-10-13 | Melford Scientific, LLC | Compositions of proton pump inhibitors, kits and methods of their use to treat diabetes |
| US20100292217A1 (en) * | 2009-05-14 | 2010-11-18 | Gilead Palo Alto, Inc. | Ranolazine for the treatment of cns disorders |
| JO3183B1 (ar) * | 2010-01-29 | 2018-03-08 | Regeneron Pharma | طرق لمعالجة أمراض المناعة الذاتية مضادات dll4 |
| TW201717919A (zh) | 2015-07-02 | 2017-06-01 | 國際藥品股份公司 | 雷諾多重壓縮錠劑 |
| WO2018001582A1 (en) | 2016-06-30 | 2018-01-04 | Interquim, S.A. | Ranolazine multiple compressed tablets |
| CN110812344A (zh) * | 2019-12-17 | 2020-02-21 | 卓和药业集团有限公司 | 一种治疗糖尿病合并心绞痛的药物组合物及制备方法 |
| GR1010510B (el) * | 2022-06-07 | 2023-07-20 | Ελπεν Α.Ε. Φαρμακευτικη Βιομηχανια, | Στερεες φαρμακοτεχνικες μορφες παρατεταμενης αποδεσμευσης ρανολαζινης |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4173626A (en) | 1978-12-11 | 1979-11-06 | Merck & Co., Inc. | Sustained release indomethacin |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US4567264A (en) | 1983-05-18 | 1986-01-28 | Syntex (U.S.A.) Inc. | Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| EP0283168A3 (en) * | 1987-03-16 | 1989-06-14 | American Home Products Corporation | Fluorooxirane carboxylates |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| IE80710B1 (en) | 1989-06-23 | 1998-12-16 | Syntex Inc | Ranolazine and related piperazines used in the treatment of tissues experiencing a physical or chemical insult |
| US5278192A (en) | 1992-07-02 | 1994-01-11 | The Research Foundation Of State University Of New York | Method of vasodilator therapy for treating a patient with a condition |
| US5455045A (en) | 1993-05-13 | 1995-10-03 | Syntex (U.S.A.) Inc. | High dose formulations |
| AU774628B2 (en) * | 1998-08-11 | 2004-07-01 | Governors Of The University Of Alberta, The | Compositions and methods for identifying mammalian malonyl coa decarboxylase inhibitors, agonists and antagonists |
| US6303607B1 (en) | 1998-09-10 | 2001-10-16 | Cv Therapeutics, Inc. | Method for administering a sustained release ranolanolazine formulation |
| US6479496B1 (en) | 1998-09-10 | 2002-11-12 | Cv Therapeutics, Inc. | Methods for treating angina with ranolazine |
| US20050245502A1 (en) | 1999-08-23 | 2005-11-03 | Phoenix Biosciences | Treatments for viral infections |
| US6803457B1 (en) | 1999-09-30 | 2004-10-12 | Pfizer, Inc. | Compounds for the treatment of ischemia |
| WO2001060348A2 (en) | 2000-02-18 | 2001-08-23 | Cv Therapeutics, Inc. | Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure |
| FR2805463B1 (fr) * | 2000-02-25 | 2003-01-24 | Adir | UTILISATION DE LA TRIMETAZIDINE POUR L'OBTENTION DE COMPOSITIONS PHARMACEUTIQUES DESTINEES A INHIBER L'ACYL-CoA ACETYLTRANSFERASE |
| US20030220312A1 (en) | 2000-05-11 | 2003-11-27 | G.D. Searle & Co. | Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of cardiovascular disorders |
| CN103356996A (zh) | 2000-05-19 | 2013-10-23 | 埃米林药品公司 | Glp-1用于制备治疗急性冠脉综合征的药物的用途 |
| US20020052377A1 (en) | 2000-07-21 | 2002-05-02 | Wolff Andrew A. | Method for treating angina |
| AU7804501A (en) | 2000-07-27 | 2002-02-13 | Pharmacia Corp | Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure |
| US6423705B1 (en) | 2001-01-25 | 2002-07-23 | Pfizer Inc. | Combination therapy |
| IL156585A0 (en) | 2001-01-26 | 2004-01-04 | Schering Corp | Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions |
| EP1406898B1 (en) * | 2001-07-19 | 2005-04-06 | Cv Therapeutics, Inc. | Substituted piperazine compounds and their use as fatty acid oxidation inhibitors |
| US20030220310A1 (en) | 2001-07-27 | 2003-11-27 | Schuh Joseph R. | Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure |
| US20050250676A1 (en) | 2001-11-19 | 2005-11-10 | Aventis Pharma Deutschland Gmbh | Method of activating insulin receptor substrate-2 to stimulate insulin production |
| EP1472214A2 (en) | 2002-02-08 | 2004-11-03 | SmithKline Beecham Corporation | Compounds for inhibiting insulin secretion and methods related thereto |
| US20080109040A1 (en) | 2002-04-04 | 2008-05-08 | Luiz Belardinelli | Method of treating arrhythmias |
| US20030220344A1 (en) | 2002-04-04 | 2003-11-27 | Luiz Belardinelli | Method of treating arrhythmias |
| AU2003248558B8 (en) | 2002-05-21 | 2009-07-09 | Gilead Sciences, Inc. | Method of treating diabetes |
| US8822473B2 (en) | 2002-05-21 | 2014-09-02 | Gilead Sciences, Inc. | Method of treating diabetes |
| JP2006523104A (ja) | 2003-03-05 | 2006-10-12 | メタボレックス インコーポレーティッド | 糖尿病およびβＴＲＰを含む関連疾患の治療および診断のための方法および組成物 |
| AU2004248187A1 (en) | 2003-06-12 | 2004-12-23 | University Of Colorado System Technology | Systems and methods for treating human inflammatory and proliferative diseases and wounds, with fatty acid metabolism inhibitors and/or glycolytic inhibitors |
| US7060723B2 (en) | 2003-08-29 | 2006-06-13 | Allergan, Inc. | Treating neurological disorders using selective antagonists of persistent sodium current |
| US7510710B2 (en) | 2004-01-08 | 2009-03-31 | The Regents Of The University Of Colorado | Compositions of UCP inhibitors, Fas antibody, a fatty acid metabolism inhibitor and/or a glucose metabolism inhibitor |
| JP2008500347A (ja) | 2004-05-24 | 2008-01-10 | ニュー・ヨーク・ユニヴァーシティー | 高血糖症による血糖の急激な増加及び／又は急激な遊離脂肪酸流動の増加の病理学的影響の治療方法又は予防方法 |
| JP2008519770A (ja) | 2004-11-09 | 2008-06-12 | シーブイ・セラピューティクス・インコーポレイテッド | 心不全の処置における左室リモデリングを逆転させるための少なくとも１種のリモデリング物質と併用するラノラジンの使用 |
| US20060177502A1 (en) | 2005-01-06 | 2006-08-10 | Srikonda Sastry | Sustained release pharmaceutical formulations |
| EP1865945A4 (en) | 2005-03-11 | 2008-05-21 | Hong Kong Nitric Oxide Ltd | TREATMENT COMBINATION FOR ENDOTHELIAL DISORDERS, ANGINA AND DIABETES |
| CA2670651A1 (en) | 2006-12-21 | 2008-07-03 | Cv Therapeutics, Inc. | Reduction of cardiovascular symptoms |
| US20080193530A1 (en) | 2007-02-13 | 2008-08-14 | Brent Blackburn | Use of ranolazine for the treatment of non-coronary microvascular diseases |
| CA2678515A1 (en) | 2007-02-13 | 2008-08-21 | Cv Therapeutics, Inc. | Use of ranolazine for the treatment of cardiovascular diseases |
| CA2678319A1 (en) | 2007-02-13 | 2008-08-21 | Cv Therapeutics, Inc. | Use of ranolazine for the treatment of coronary microvascular diseases |
| US20090111826A1 (en) | 2007-02-13 | 2009-04-30 | Louis Lange | Use of ranolazine for the treatment of cardiovascular diseases |
| US20090312340A1 (en) | 2007-02-13 | 2009-12-17 | Whedy Wang | Use of ranolazine for the treatment of cardiovascular diseases |
| WO2008116083A1 (en) | 2007-03-22 | 2008-09-25 | Cv Therapeutics, Inc. | Use of ranolazine for elevated brain-type natriuretic peptide |
| ES2402675T3 (es) | 2007-05-31 | 2013-05-07 | Gilead Palo Alto, Inc. | Ranolazina para el péptido natriurético de tipo cerebral a niveles elevados |
| CN101678017A (zh) | 2007-05-31 | 2010-03-24 | Cv医药有限公司 | 治疗糖尿病的方法 |
| CA2713521A1 (en) | 2008-02-06 | 2009-08-13 | Gilead Palo Alto, Inc. | Use of ranolazine for treating pain |
| EP2337559A2 (en) | 2008-09-04 | 2011-06-29 | Gilead Sciences, Inc. | Method of treating atrial fibrillation |
| US20100130436A1 (en) | 2008-11-25 | 2010-05-27 | Gilead Palo Alto, Inc. | Co-administration of ranolazine and cardiac glycosides |
| US20100292217A1 (en) | 2009-05-14 | 2010-11-18 | Gilead Palo Alto, Inc. | Ranolazine for the treatment of cns disorders |
| TWI508726B (zh) | 2009-12-21 | 2015-11-21 | Gilead Sciences Inc | 治療心房纖維性顫動之方法 |
| TW201215392A (en) | 2010-06-16 | 2012-04-16 | Gilead Sciences Inc | Use of ranolazine for treating pulmonary hypertension |
-
2003
- 2003-05-21 AU AU2003248558A patent/AU2003248558B8/en not_active Ceased
- 2003-05-21 RU RU2004133670/14A patent/RU2320343C2/ru not_active IP Right Cessation
- 2003-05-21 ES ES03755446.6T patent/ES2523873T3/es not_active Expired - Lifetime
- 2003-05-21 BR BR0311161-0A patent/BR0311161A/pt not_active Application Discontinuation
- 2003-05-21 EP EP03755446.6A patent/EP1505977B1/en not_active Expired - Lifetime
- 2003-05-21 CN CNB038113236A patent/CN100551370C/zh not_active Expired - Fee Related
- 2003-05-21 CA CA2486712A patent/CA2486712C/en not_active Expired - Fee Related
- 2003-05-21 WO PCT/US2003/016277 patent/WO2003099281A2/en not_active Ceased
- 2003-05-21 NZ NZ536678A patent/NZ536678A/en not_active IP Right Cessation
- 2003-05-21 JP JP2004506805A patent/JP4546824B2/ja not_active Expired - Fee Related
- 2003-05-21 EP EP10011229A patent/EP2332540A1/en not_active Withdrawn
- 2003-05-21 MX MXPA04011530A patent/MXPA04011530A/es active IP Right Grant
- 2003-05-21 KR KR1020047018803A patent/KR101030943B1/ko not_active Expired - Fee Related
- 2003-05-21 IL IL16530403A patent/IL165304A0/xx unknown
- 2003-05-21 US US10/443,314 patent/US20040063717A1/en not_active Abandoned
-
2004
- 2004-11-18 IL IL165304A patent/IL165304A/en active IP Right Grant
- 2004-11-19 ZA ZA2004/09331A patent/ZA200409331B/en unknown
- 2004-12-20 NO NO20045554A patent/NO330336B1/no not_active IP Right Cessation
-
2010
- 2010-04-07 US US12/755,931 patent/US8314104B2/en not_active Expired - Fee Related
-
2011
- 2011-06-28 IL IL213806A patent/IL213806A0/en unknown
- 2011-06-28 IL IL213809A patent/IL213809A0/en unknown
-
2012
- 2012-10-18 US US13/655,252 patent/US8883750B2/en not_active Expired - Fee Related
-
2014
- 2014-09-03 US US14/476,650 patent/US20140378465A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005532331A5 (https=) | ||
| RU2361868C2 (ru) | Новые производные тиазола | |
| RU2004133670A (ru) | Способ лечения диабета | |
| FR20C1018I1 (fr) | Composition pharmaceutique comprenant du glycopyrrolate et un agoniste du récepteur beta2 adrénergique | |
| JP2005528393A5 (https=) | ||
| CA2513092A1 (en) | Compounds for the treatment of metabolic disorders | |
| RU2420522C2 (ru) | Новый класс ингибиторов гистондеацетилаз | |
| WO2006046623A1 (ja) | 溶解性及び安定性の改善された固形製剤及びその製造方法 | |
| RU2002123350A (ru) | Дипептиднитрильные ингибиторы катепсина К | |
| JP2001526218A5 (https=) | ||
| RU2004104625A (ru) | Аналоги простагландинов в качестве агонистов рецептора ep4 | |
| JP2005501120A5 (https=) | ||
| CA2521621A1 (en) | Compounds for the treatment of metabolic disorders | |
| JP2005511547A5 (https=) | ||
| CA2522738A1 (en) | Compounds for the treatment of metabolic disorders | |
| JP2005526696A5 (https=) | ||
| RU99122343A (ru) | Производные 2-(иминометил)аминофенила, способ их получения, их применение в качестве лекарственных средств и фармацевтические композиции на их основе | |
| KR960041168A (ko) | 베타-아드레날린 효능성 작용물질 | |
| JP3125319B2 (ja) | 水難溶性薬物の医薬組成物 | |
| JP2007500700A5 (https=) | ||
| RU2007108415A (ru) | Новое циклическое производное аминобензойной кислоты | |
| JP2006511606A5 (https=) | ||
| JP2005519885A5 (https=) | ||
| RU2006113550A (ru) | Циклогексильные производные, замещенные аминоалкиламидами | |
| JP2005526138A5 (https=) |